Does insurance cover Ozempic in Texas?

If you’ve been considering medications like Wegovy, Ozempic, or Mounjaro for weight loss, you’re not alone. These breakthrough GLP-1 medications have transformed weight management—but there’s a critical question on everyone’s mind: Will insurance actually pay for them?

The short answer: it’s complicated. Coverage varies dramatically depending on your insurance type, the specific medication, and even which state you live in. While most insurers readily cover these drugs for diabetes, getting approval for weight loss often feels like navigating a maze of prior authorizations, step therapy requirements, and outright exclusions.

In this comprehensive guide, we’ll break down exactly what you need to know about insurance coverage for weight loss medications in 2025—including which plans cover what, how to navigate denials, and what your options are if insurance won’t help.

Understanding GLP-1 Medications: What’s the Difference?

Before diving into coverage, it’s important to understand the key players:

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with a BMI ≥30 or ≥27 with weight-related health conditions. It’s the same active ingredient as Ozempic, but formulated and approved solely for obesity treatment.

Ozempic (semaglutide) is FDA-approved for Type 2 diabetes management. While it causes weight loss as a side effect, using it for weight loss alone is considered off-label—and most insurers won’t cover off-label uses.

Mounjaro (tirzepatide) is approved for Type 2 diabetes. Its weight-loss counterpart, Zepbound, received FDA approval for obesity treatment in late 2023, but many insurers still restrict coverage tightly.

This distinction matters enormously for insurance coverage. Diabetes medications are typically covered as essential health benefits, while weight-loss drugs often face exclusions or strict limitations.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: The Mixed Picture

What Most Private Plans Cover

If you have employer-sponsored or individual marketplace insurance, here’s what you’re likely facing:

For Diabetes Use: Most commercial insurers cover Ozempic and Mounjaro when prescribed for Type 2 diabetes. These medications are typically placed on Tier 3 (non-preferred brand) or Tier 4 (specialty) formularies, meaning your copay could range from $50 to several hundred dollars depending on your plan design.

For Weight Loss: Coverage gets murky. Many employer plans—possibly the majority—exclude weight-loss medications entirely as optional benefits due to their high cost. According to industry analyses, large employers increasingly face difficult decisions about whether to cover these drugs, with costs potentially reaching thousands per member annually.

Plans that do cover Wegovy almost universally require:

• Prior authorization with extensive documentation
• BMI threshold of ≥30, or ≥27 with at least one obesity-related comorbidity (like hypertension, high cholesterol, or prediabetes)
• Documented lifestyle intervention of at least 6 months, including supervised diet and exercise programs
• Step therapy requirements showing you’ve tried and failed on older, cheaper weight-loss medications
• Ongoing re-evaluation every 3-6 months to demonstrate at least 5% weight loss or therapy may be discontinued

Prior Authorization: The Gatekeeper

Prior authorization (PA) is standard for all three medications, but the requirements differ dramatically:

For diabetes medications (Ozempic, Mounjaro), PA typically confirms your Type 2 diabetes diagnosis and may require proof you’ve tried first-line medications like metformin first. This process, while sometimes frustrating, is relatively straightforward.

For weight-loss use (Wegovy), PA becomes significantly more rigorous. Insurers like Aetna require documentation that includes:

• Current BMI calculation with supporting weight and height measurements
• Complete medical history showing obesity-related complications
• Detailed records of previous weight-loss attempts, including dates, methods, and outcomes
• Physician attestation that lifestyle modifications alone have been insufficient
• Confirmation the patient doesn’t have contraindications (like medullary thyroid cancer history)

The process typically takes 5-7 business days for initial decisions, though complex cases or additional information requests can extend this to 2-3 weeks.

Common Denial Reasons and How to Overcome Them

Understanding why claims get denied helps you build a stronger case from the start:

Insufficient BMI documentation: If your recorded BMI falls even slightly below the threshold, or if measurements are outdated, expect a denial. Solution: Ensure your provider documents current, accurate height and weight measurements in your medical record.

Inadequate lifestyle modification records: Vague statements like ‘patient tried diet and exercise’ won’t cut it. Insurers want specific documentation of supervised programs with dates, duration, methods used, and outcomes. Working with a registered dietitian or documented weight-loss program for 6+ months creates the paper trail insurers require.

Missing comorbidity documentation: If your BMI is 27-29.9, you’ll need documented obesity-related conditions. Make sure conditions like hypertension, dyslipidemia, or prediabetes are clearly noted in your medical record with supporting lab values or blood pressure readings.

Step therapy failure: Some insurers require trying older medications (like phentermine or orlistat) first. If you have contraindications to these medications, your doctor should document why they’re inappropriate for you.

Off-label use denials: Requesting Ozempic for weight loss when you don’t have diabetes will almost certainly result in denial, as insurers only cover FDA-approved indications.

Medicare Coverage: Limited but Evolving

Current Medicare Part D Rules

Federal law prohibits Medicare Part D from covering medications used solely for weight loss or weight gain. This exclusion has been in place since the program’s inception and applies to Wegovy and Zepbound.

However, there’s an important exception: Medicare can cover these medications for other FDA-approved uses. In March 2024, Medicare announced it would cover Wegovy for cardiovascular risk reduction in patients with obesity and established cardiovascular disease—not for weight loss per se, but for preventing heart attacks and strokes.

This means if you have Medicare and meet specific criteria (obesity plus documented heart disease), you may get coverage. But coverage purely for weight management remains prohibited.

What About Ozempic and Mounjaro on Medicare?

Both medications are covered under Medicare Part D when prescribed for Type 2 diabetes. They’re treated like other diabetes medications, typically placed on higher tiers with corresponding copays or coinsurance.

The catch: Medicare will deny coverage if the prescription is written for weight loss alone. Your diagnosis code and prescribing reason must align with the approved diabetes indication.

Medicare Advantage Plans

Some Medicare Advantage plans began offering limited obesity medication coverage in 2025 as a supplemental benefit, but this remains the exception rather than the rule. Coverage, when available, comes with strict criteria and often significant cost-sharing.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for weight-loss medications varies dramatically by state, and the landscape shifted significantly in late 2025 as states grappled with budgetary pressures.

States with Coverage (Declining)

As of early 2025, only about 13 states provided Medicaid coverage for GLP-1 weight-loss medications. However, several states announced they’re eliminating this coverage effective January 1, 2026, due to unsustainable costs:

California (Medi-Cal): Covered Wegovy with prior authorization through December 2025, requiring BMI ≥30 (or ≥27 with comorbidity) and documented 6-month supervised diet attempts. Starting January 1, 2026, Medi-Cal will no longer cover Wegovy, Saxenda, or Zepbound for adult weight loss. Pediatric patients may still access these medications through Early and Periodic Screening, Diagnostic and Treatment (EPSDT) provisions.

Pennsylvania: Added coverage in 2023 with strict criteria, but announced it will discontinue coverage for weight-loss GLP-1s in January 2026 as a budget-saving measure. The state faced rapidly escalating costs as utilization increased beyond projections.

New York: Continues to cover Wegovy through its NYRx formulary with prior authorization. Criteria mirror FDA labeling (BMI ≥30 or ≥27 + comorbidity), documented lifestyle modification, and quantity limits of 4 pens per 28 days.

States Without Coverage

Many large states explicitly exclude obesity medications from Medicaid coverage:

Texas: Medicaid completely excludes all obesity medications for adults 21 and older. Non-formulary requests for drugs like Wegovy, Saxenda, or Qsymia are denied as a matter of policy. Pediatric patients under 21 may request coverage through EPSDT provisions on a case-by-case basis.

Florida: Does not cover weight-loss drugs under Medicaid, utilizing the optional federal exclusion. Only GLP-1s prescribed for Type 2 diabetes (like Ozempic) receive coverage.

Illinois: Has not adopted Medicaid coverage for anti-obesity medications as of 2025, despite expanding coverage for state employees.

The EPSDT Exception

One important caveat: Children and adolescents under 21 enrolled in Medicaid may access obesity medications through EPSDT provisions even in states that don’t cover them for adults. EPSDT requires states to provide medically necessary services for pediatric enrollees, potentially including FDA-approved weight-loss medications when clinically appropriate.

The Real-World Coverage Process: What to Expect

Step 1: Provider Assessment and Documentation

Your healthcare provider plays a crucial role in insurance approval. They’ll need to:

• Document your current BMI with precise measurements
• Record any obesity-related health conditions (hypertension, sleep apnea, fatty liver disease, etc.)
• Create a comprehensive record of previous weight-loss attempts, including formal programs, dietary changes, and exercise regimens
• Establish baseline labs (glucose, lipids, liver function) and cardiovascular risk assessment
• Write a detailed letter of medical necessity explaining why medication is appropriate

Working with providers experienced in weight management—like those available through platforms like Klarity Health—can streamline this process, as they understand exactly what documentation insurers require.

Step 2: Prior Authorization Submission

Your provider or pharmacy submits the PA request to your insurance company with supporting documentation. This includes:

• Completed PA form specific to your insurer
• Clinical notes justifying medical necessity
• Records of previous interventions
• Treatment plan outlining monitoring and follow-up

Most insurers respond within 5-7 business days for standard requests. Some states require 72-hour responses for urgent medication requests.

Step 3: Dealing with Denials

If your initial request is denied (which happens frequently), don’t give up:

Review the denial letter carefully. It should specify exactly why coverage was denied—whether due to insufficient documentation, failure to meet criteria, or plan exclusion.

Gather additional evidence. If documentation was incomplete, work with your provider to supply missing information. Detailed records of your weight-loss journey, comorbidity documentation, or specialist letters can strengthen an appeal.

Submit a formal appeal. Most insurers have a two-level appeal process. First-level appeals often succeed when criteria are actually met but documentation was initially inadequate.

Request an external review. If internal appeals fail and you believe coverage should apply based on plan documents, you can often request independent external review.

Consider an alternative approach. If your plan categorically excludes weight-loss drugs, appealing won’t help. Instead, explore manufacturer assistance programs or alternative coverage through a different medication (like using a diabetes-approved GLP-1 if you have prediabetes).

Success rates for appeals vary, but persistence pays off when you genuinely meet coverage criteria. Anecdotal reports suggest 30-50% of initial denials are overturned when patients and providers submit comprehensive supporting documentation.

Telehealth and Insurance Coverage: Good News

One bright spot in the coverage landscape: telehealth visits for weight management are widely covered by insurance in 2025.

Telehealth Parity Laws

More than 40 states have enacted telehealth parity laws requiring private insurers to cover virtual care equivalently to in-person visits. For weight management consultations, nutritional counseling, and medication management, this means:

• Same copays/coinsurance as office visits
• No additional restrictions on virtual care
• Coverage for asynchronous (messaging) consultations in many states

What This Means for Accessing GLP-1s

You can typically:

• Have your initial weight-loss consultation via video visit
• Receive ongoing medication management through telehealth
• Complete required lifestyle counseling sessions virtually
• Have prescriptions sent electronically to your pharmacy

Platforms like Klarity Health make this particularly convenient, offering same-day or next-day appointments with providers who understand both the clinical aspects of weight management and the insurance landscape. Klarity Health accepts both insurance and cash pay, with transparent pricing—so even if your initial consultation is out-of-network, you know exactly what to expect. More importantly, Klarity’s network of licensed providers can prescribe GLP-1 medications and help navigate the prior authorization process, whether you’re using insurance or paying out-of-pocket.

The key is confirming your telehealth provider is in-network with your insurance plan, or understanding the out-of-network cost-sharing if they’re not. Many major insurers now contract with telehealth platforms or allow your existing PCP to conduct virtual visits.

When Insurance Won’t Cover: Your Best Options

If your insurance denies coverage or doesn’t cover weight-loss medications at all, you’re not without options. Recent manufacturer pricing programs and discount initiatives have dramatically reduced cash-pay costs.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly have introduced significant price reductions:

Wegovy/Ozempic (Novo Nordisk):

• GoodRx partnership program: $199/month for the first two months, then $349/month ongoing (launched November 2025)
• NovoCare Wegovy Access Program: Direct retail pharmacy pricing at $349/month (down from previous $499)
• Copay savings card: For commercially insured patients, as low as $0 copay (up to $225 monthly savings) when insurance partially covers the drug

Mounjaro/Zepbound (Eli Lilly):

• LillyDirect program: Single-dose vials available at $299-$449/month depending on dose (launched late 2025)
• Mounjaro Savings Card: $25/month for commercially insured Type 2 diabetes patients (covers up to $500 monthly)

These programs represent 60-75% discounts off list prices (~$1,000-$1,350/month), making self-pay significantly more accessible than in previous years.

Patient Assistance Programs

Both manufacturers offer free medication to qualifying uninsured or underinsured patients:

Novo Nordisk Patient Assistance Program: Provides free Wegovy or Ozempic for up to 12 months for patients meeting income criteria (typically ≤400% of federal poverty level, though exact thresholds vary). Application through NovoCare requires proof of income and insurance status.

Lilly Cares Foundation: Similar assistance for Mounjaro/Zepbound, providing free medication to eligible patients. Applications require healthcare provider involvement and financial documentation.

Important Cautions About Compounded Alternatives

Some telehealth companies and wellness clinics offer compounded semaglutide or tirzepatide at significantly lower prices (often $200-$400/month). Proceed with extreme caution:

• These are not FDA-approved medications
• Quality, purity, and dosing accuracy aren’t guaranteed
• The FDA has issued warnings about compounded GLP-1s due to safety concerns
• If supply issues are resolved (Novo and Lilly are ramping up production), compounding may become illegal
• Insurance never covers compounded versions

While the cost savings are tempting, the risks may outweigh benefits. Stick with FDA-approved brand medications when possible, utilizing manufacturer programs to reduce costs.

Older Weight-Loss Medications

If GLP-1s remain unaffordable, several older medications offer more modest weight-loss results at much lower costs:

• Phentermine: Generic appetite suppressant, $20-$50/month, widely covered by insurance for short-term use
• Orlistat (Alli/Xenical): Fat absorption blocker, $50-$100/month, over-the-counter and prescription versions
• Phentermine-topiramate (Qsymia): Combination medication, $150-$200/month, some insurance coverage

These won’t produce the 15-20% weight loss seen with GLP-1s, but average 5-10% weight reduction—still clinically meaningful—at a fraction of the cost.

Practical Strategies for Getting Coverage

Based on insurance coverage patterns and successful appeals, here are actionable strategies:

1. Choose the Right Medication for Your Situation

If you have Type 2 diabetes or prediabetes, ask your provider about prescribing Ozempic or Mounjaro for diabetes management. The weight loss is a ‘bonus’ covered benefit, with far fewer authorization hurdles than Wegovy.

If you don’t have diabetes but meet BMI criteria, Wegovy is your target medication. Don’t try to use Ozempic off-label—insurers will deny it.

2. Build Your Documentation Before Requesting

Spend 3-6 months creating the paper trail insurers want:

• Work with a registered dietitian or structured weight-loss program and document every session
• Keep a detailed food and exercise journal
• Get regular weight measurements documented in your medical record
• Address any obesity-related health conditions with your doctor and get them documented with supporting data

This preparation dramatically improves approval odds.

3. Work with Experienced Providers

Providers who regularly prescribe these medications understand exactly what insurers need. They can:

• Write comprehensive letters of medical necessity
• Code diagnoses appropriately
• Navigate PA portals efficiently
• Know which arguments work with specific insurers

Specialized weight management clinics or telehealth platforms focused on metabolic health often have higher approval rates than general practitioners simply because of their experience with the process.

4. Don’t Accept the First Denial

Initial denials are frustratingly common—even when criteria are met. Systematic appeals with additional documentation succeed in a substantial percentage of cases. Be persistent.

5. Time Your Request Strategically

If possible, initiate coverage requests early in the calendar year when your deductible resets. Some plans impose annual or lifetime limits on specialty medications; getting approved early maximizes your covered months.

Also, watch for plan year changes. If your employer is adding weight-loss medication coverage (or dropping it), timing matters.

6. Consider Switching Plans During Open Enrollment

If you know you’ll need weight-loss medication long-term, carefully review plan documents during open enrollment. Some plans explicitly cover obesity treatment while others exclude it. If two plans cost similarly, choosing the one with weight-management benefits could save thousands annually.

The Future of Coverage: What’s Coming

Legislative Momentum

The ‘Treat and Reduce Obesity Act’ has been introduced in multiple Congressional sessions, proposing to require Medicare coverage for obesity treatment, including medications. While it hasn’t passed yet, growing recognition of obesity as a chronic disease—not a lifestyle choice—is shifting the conversation.

Several states are considering legislation requiring coverage of obesity medications in their Medicaid programs and state-regulated insurance plans.

Market Dynamics

Competition is intensifying in the GLP-1 market. Generic versions won’t arrive until patents expire in the 2030s, but:

• More pharmaceutical companies are developing competing GLP-1 and dual-agonist medications
• Increased competition may drive down prices
• Oral versions are in development, potentially with different cost structures
• Once-weekly or even once-monthly formulations may improve compliance and reduce costs

Employer Plan Evolution

As evidence accumulates showing GLP-1 medications reduce healthcare costs long-term (by preventing diabetes, cardiovascular events, and obesity-related cancers), more employers may add coverage. Early data suggests every dollar spent on these medications could save $2-3 in downstream healthcare costs over 5-10 years.

However, short-term budget impacts remain a barrier, especially for self-insured employers concerned about immediate spending increases.

Making Your Decision: Insurance vs. Self-Pay

For many people, the decision comes down to practical math:

If your insurance covers with reasonable cost-sharing (say, a $50-100 monthly copay after meeting a manageable deductible), using insurance makes sense despite the PA hassles.

If coverage requires multiple appeals, months of documentation, and uncertain approval, weigh that time and stress against manufacturer programs offering $349/month guaranteed pricing. For some, the predictability and simplicity of self-pay wins.

If you’re uninsured or underinsured with qualifying income, patient assistance programs offering free medication for a year may be your best path while you work on longer-term insurance solutions.

There’s no single right answer—your finances, patience for bureaucracy, and urgency to start treatment all factor in.

Getting Started with Confidence

Navigating insurance coverage for weight-loss medications can feel overwhelming, but understanding the landscape empowers you to make informed decisions and advocate effectively for yourself.

Remember:

• Coverage depends on your specific insurance type, the medication, and your clinical situation
• Diabetes use of GLP-1s is widely covered; weight-loss use faces more barriers
• Thorough documentation and persistence significantly improve approval odds
• When insurance won’t help, manufacturer programs and patient assistance can bridge the gap
• Telehealth access makes starting treatment easier than ever, with platforms like Klarity Health offering convenient, transparent options for both insured and self-pay patients

Whether you’re just beginning to explore these medications or fighting an insurance denial, you now have the knowledge to navigate the system. These medications represent a genuine breakthrough in weight management—and with the right strategy, they’re increasingly accessible regardless of your insurance situation.

Ready to take the next step? Consider scheduling a consultation with a weight management specialist who can assess your situation, help build your case for insurance coverage, and discuss all your options. Klarity Health offers same-day and next-day appointments with experienced providers who understand both the clinical side of weight loss and the insurance landscape—and with transparent pricing and flexible payment options, you can get started on your path to healthier weight, however you choose to pay.

Frequently Asked Questions

Does commercial insurance cover Wegovy?
Coverage varies widely. Many employer plans exclude weight-loss medications entirely. Plans that do cover Wegovy require prior authorization, documentation of BMI ≥30 (or ≥27 with comorbidities), and proof of 6+ months of lifestyle intervention. Large insurers like Aetna and Cigna have strict criteria even when they offer coverage.

Will Medicare pay for Ozempic for weight loss?
No. Medicare Part D cannot cover medications used solely for weight loss due to federal law. However, Medicare does cover Ozempic when prescribed for Type 2 diabetes, and covers Wegovy specifically for cardiovascular risk reduction in patients with obesity and heart disease (not purely for weight loss).

Which states cover weight-loss medications on Medicaid?
As of early 2025, only about 13 states cover GLP-1 weight-loss medications through Medicaid, and this number is declining. California and Pennsylvania are eliminating coverage January 1, 2026. New York continues coverage with strict prior authorization. Texas, Florida, and Illinois do not cover obesity medications for adult Medicaid enrollees.

What’s the best way to get insurance to cover Wegovy?
Build comprehensive documentation before requesting coverage: work with a registered dietitian for 6+ months, document all weight-loss attempts, ensure your BMI and comorbidities are accurately recorded in your medical record, and work with an experienced provider who can write a detailed letter of medical necessity. Be prepared to appeal if initially denied.

How much does Wegovy cost without insurance?
List price is approximately $1,350/month, but manufacturer programs have dramatically reduced cash-pay costs. The GoodRx partnership with Novo Nordisk offers $199/month for the first two months, then $349/month ongoing. Novo’s direct NovoCare program offers $349/month at retail pharmacies.

Can I use a manufacturer coupon if my insurance doesn’t cover weight-loss drugs?
It depends. If your plan explicitly excludes the drug (it’s not on the formulary at all), manufacturer coupons often provide a fixed discount. However, if the drug is on formulary but denied for medical necessity, some coupons only work when insurance pays something. Read the coupon terms carefully, and note that coupons cannot be used with government insurance programs (Medicare, Medicaid).

Is telehealth covered for weight-loss treatment?
Yes, most insurance plans cover telehealth visits for weight management the same as in-person visits, thanks to telehealth parity laws in over 40 states. Your nutritional counseling, medication management, and follow-up appointments can typically be conducted virtually with the same copays as office visits, as long as you use an in-network provider.

Research Currency Statement

Verified as of December 17, 2025

This article’s insurance coverage information, formulary details, and pricing data were compiled and verified in mid-December 2025. Given the rapidly evolving landscape of GLP-1 medication coverage, we recommend confirming specific details with your insurance plan before making treatment decisions.

Citations

1. Aetna Clinical Policy Bulletin – Weight Loss GLP-1 Agonists (May 2024)
   www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss(BMI35)GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR05-2024.html
   Official insurer prior authorization criteria detailing BMI requirements, lifestyle intervention documentation, and coverage conditions.

2. Kaiser Family Foundation – Medicaid Coverage of and Spending on GLP-1s (November 2024)
   www.kff.org/medicaid/issue-brief/medicaid-coverage-of-and-spending-on-glp-1s
   Comprehensive analysis of state-by-state Medicaid coverage policies, finding approximately 13 states cover obesity GLP-1 medications as of 2024.

3. California Department of Health Care Services – Medi-Cal GLP-1 Policy Update (December 2025)
   www.cmadocs.org/newsroom/news/view/ArticleId/51074
   Official announcement that California Medi-Cal will discontinue coverage of Wegovy, Saxenda, and Zepbound for weight loss effective January 1, 2026.

4. GoodRx Press Release – New Weight Loss Pricing Program (November 17, 2025)
   www.businesswire.com/news/home/20251117268209/en
   Announcement of partnership with Novo Nordisk offering Wegovy and Ozempic at $199/month introductory pricing (first two months) and $349/month ongoing.

5. Pennsylvania Health Law Project – PA Medicaid Coverage of Weight Loss Drugs (August 2024)
   www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs
   Details Pennsylvania Medicaid’s coverage criteria for GLP-1 weight-loss medications, including BMI requirements and prior authorization process (note: coverage ending January 2026).

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499